BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids, derived from a protein naturally found in human gastric juice. It is widely studied in preclinical research for its role in tissue repair, angiogenesis, and cytoprotective signalling.

How do I reconstitute BPC-157?

Reconstitute with 1-2 ml of bacteriostatic water. Allow the vial to reach room temperature, inject solvent gently down the inside wall, and swirl gently. Never shake. Store reconstituted solution at 2-8°C and use within 4-6 weeks.

What purity is BioLab's BPC-157?

Every batch is independently tested via HPLC and mass spectrometry to confirm 99%+ purity and correct molecular identity. A batch-specific Certificate of Analysis is available with every order.

How should I store BPC-157?

Store lyophilised vials at -20°C, protected from light and moisture. Once reconstituted with bacteriostatic water, store at 2-8°C and use within 4-6 weeks. Avoid repeated freeze-thaw cycles.

PT-141 10 mg

£30.00

PT-141 (Bremelanotide) is a synthetic melanocortin receptor agonist derived from Melanotan II. Unlike PDE5 inhibitors, PT-141 acts centrally on the MC3R and MC4R receptors in the hypothalamus. Available to buy in the UK — 10 mg, HPLC-verified 99%+ purity.

Purity: ≥99% (HPLC & MS)
Quantity: 10 mg per vial
CAS: 189691-06-3
Amino Acids: 7 (cyclic heptapeptide)
Storage: -20°C (lyophilised) · 2–8°C (reconstituted)

Categories: All Peptides, Sexual Health

Description
Reviews (0)

PT-141 10 mg | Melanocortin Receptor Research Peptide

PT-141 (Bremelanotide) is a cyclic heptapeptide and selective melanocortin-4 receptor (MC4R) agonist. Originally developed as a derivative of Melanotan II, PT-141 was found to act on central nervous system pathways governing sexual arousal — a mechanism fundamentally different from peripheral vasodilators like PDE5 inhibitors.

Product Specifications

Molecular Weight	1,025.18 g/mol
CAS	189691-06-3
Structure	Cyclic heptapeptide (lactam bridge)
Purity	≥99% (HPLC & MS)

Research Background

Central mechanism : PT-141 activates melanocortin-3 and melanocortin-4 receptors (MC3R/MC4R) in the hypothalamus, triggering downstream signalling that influences sexual arousal pathways. This central mechanism distinguishes it from PDE5 inhibitors that act peripherally on vascular smooth muscle.

Preclinical sexual function studies : PT-141 has been investigated in both male and female preclinical models, where it demonstrated effects on sexual motivation and arousal independent of hormonal status — an unusual profile among compounds studied for sexual function.

Melanocortin system research : Beyond sexual function, the melanocortin receptor system is implicated in energy homeostasis, inflammation, and neuroprotection, making PT-141 a versatile research tool for MC4R pathway studies.